BioSpace News Archive

Ventyx Biosciences, Inc. announced that Company executives will participate in the following upcoming investor conferences.

Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced plans to present at the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY.

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at five investor conferences in September.

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, at 8:50 a.m. Eastern Time.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Mark for its Essenz™ In-Line Blood Monitor (ILBM), which provides accurate and continuous measurement of essential blood parameters to perfusionists throughout cardiopulmonary bypass (CPB) procedures.

Longboard Pharmaceuticals, Inc. announced that it will present new and encore data at the 35th International Epilepsy Congress and the American College of Clinical Pharmacology Annual Meeting.

Disc Medicine, Inc. announced that company management will participate in fireside chats at four upcoming investor conferences.

ORIC Pharmaceuticals, Inc. announced that management will participate in the following investor conferences in the first half of September.

STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced that it will participate in the Morgan Stanley Healthcare Conference in New York City on Wednesday, September 13, 2023.

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard) is an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors.